ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the recipient of a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 109,700 shares, a drop of 41.6% from the March 15th total of 187,900 shares. Based on an average daily volume of 2,590,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 4.3% of the company’s shares are short sold.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in ZyVersa Therapeutics stock. Virtu Financial LLC purchased a new stake in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 25,259 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned about 1.08% of ZyVersa Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 3.91% of the company’s stock.

ZyVersa Therapeutics Stock Performance

ZyVersa Therapeutics stock traded down $0.01 during trading hours on Friday, reaching $0.70. 122,097 shares of the company’s stock traded hands, compared to its average volume of 1,139,695. The firm’s 50 day moving average is $0.92 and its 200-day moving average is $1.29. ZyVersa Therapeutics has a fifty-two week low of $0.55 and a fifty-two week high of $6.70.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.